Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Sodium channel protein type I alpha subunit

5

Sodium channel protein type II alpha subunit

5

Sodium channel protein type III alpha subunit

5

Sodium channel protein type VIII alpha subunit

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1938

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Seizures

5

Status epilepticus

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Parke Davis

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EVMPD

5

FDA UNII

5

PUBCHEM

5

SMS_ID

5

CAS

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIEPILEPTICS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIEPILEPTICS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Hydantoin derivatives

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PHENYTOIN

6158TKW0C5

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN

B4SF212641

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN SODIUM HEPTAHYDRATE

9X1NTA9SRP

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

PHENYTOIN SODIUM

4182431BJH

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN SODIUM

7VLR55452Z

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1